Canada Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.33+0.96 (+1.80%)
At close: 04:02PM EST
54.62 +0.29 (+0.53%)
After hours: 07:58PM EST
Sign in to post a message.
  • V
    Vonomit
    God Almighty Had Been Doing Great Things in My Life But The Greatest He did Was To Have Connected Me To this trader that has turned my life around, some months ago I started investing with Ricky L. Vasquez and it was very successful I was able To Earn 50,000$ weekly with An Investment Of 10, 000$ it Been so Amazing Trading and investing with Mis Ricky L. Vasquez Platform
  • P
    Pathfinder
    The European Medicines Agency (EMA) said on Thursday it had approved Pfizer's anti-COVID-19 pill Paxlovid, becoming the first orally administered antiviral drug authorised for use in the European Union.

    "The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the oral antiviral drug Paxlovid," the EU regulator said in a statement.

    The EMA recommended "authorising Paxlovid for the treatment of COVID-19 in adults who do not require supplementary oxygen and who are at increased risk of the disease becoming severe".

    Pfizer said in December that Paxlovid reduced hospital admissions and deaths in at-risk people by up to 90 per cent when taken in the first few days after symptoms appear.
    The EMA assessed data from a study involving COVID-19 patients showing that "treatment with Paxlovid significantly reduced hospitalisations or deaths in patients who had at least one underlying condition putting them at risk of severe COVID-19".

    The majority of patients in the study were infected with the Delta variant, the EMA said, while noting that laboratory tests indicate that Paxlovid should remain effective against Omicron.

    The Pfizer pill is a combination of a new molecule, PF-07321332, and the HIV antiviral Ritonavir, which are taken as separate tablets.
  • C
    Carl
    European Commission approves PFE's Lorviqua for first line lung cancer treatment of ALK-Positive patients.
  • d
    dino
    You will have no regrets in a few months if you buy here.
    Only in a major market collapse would you see this go to $30 ever again, along with the whole lot.
    Patient for $65...l will Crack a pint for that one in the next few months.
  • C
    Carl
    Sarah Palin went out to dinner in NY while positive for COVID. The restaurant didn't check her vaccine status and it now has to alert their staff who served her that they have been exposed to COVID. I imagine they took a limo to get there and exposed the driver also. Some people think that rules are only for other people, and they can give two sheets for everyone else.
  • d
    dino
    Short term pain for PFE longs will soon be history. Friends of the trend stay tight and win 🏆
  • A
    Adam
    Australia records deadliest day of Covid pandemic as 35 cases of BA.2 Omicron variant detected
  • S
    Surf
    $57 after earnings
  • A
    AmericanPride
    it seems that the CEO all he cares about is looking good on broadcast interviews and less on what he can do for Pfizer. this company should have been in the 100's with all its innovations and medical advancements. pull your head out of the cameras and more into Pfizer.
  • C
    Carl
    CDC says third dose of vaccine is recommended for preventing hospitalizations especially in immunocompromised people.
  • C
    Carl
    Looks like a big hurt has been in the process for those who were predicting PFE to fall under $50. As we approach earnings, I expect the pressure will increase. PFE will report billions in revenues, and it should have some new on what it will be doing with the tons of money it will have to work with.
  • W
    Wisdom of Crowds
    I believe and predict PFE will be green on 10 of the next 14 days going into blowout earnings.
  • i
    ilinar
    Looks like $GTXO the most undervalued Covid play. CEO said ‘PPE sales through the roof’ in latest YouTube video, so earnings should be exciting
  • d
    dino
    Trading of PFE has been nothing unusual over the last month. It blew off at $ 61ish on high volume as sellers dumped and all that jazz and has been sloshing around now till the next move up.
    All perfectly normal in my books.
    PFE IS A BUY!!!
  • T
    Tammy
    Volume pretty low in premarket. Not many taking advantage of the 40 cent price drop on ex dividend date today. Hoping when the market opens we quickly go back up the 40 cents. Can’t wait for the dividend payment March 4th.
  • l
    louis
    to get .40cent dividend you need hold or buy stock at 1/26/2022 for record day 1/28/2022
    Pfizer earning day 2/8/2022 earning whipper is 1.18 my target $1.5 for 4 quarter on 84bil sell
    target $65 for eps =$4.5 for 2021
  • g
    guy
    Here we go to 55 today and next week 60 and after 2/8 65 -70. Every quarter it is the same scenario. Easy money.
  • C
    Carl
    Barron's just reported that COVID deaths in US hit the highest level in a year on Monday - 2,166 lives lost. It also reported that PFE's booster has been 90% effective in preventing the need for hospitalizations. Clearly the unvaccinated and under-vaccinated are being caught up with the most severe symptoms and deaths.
  • A
    Adam
    The American Academy of Pediatrics and the Children’s Hospital Association says more than 1.1 million children tested positive for COVID-19 in the week ending Jan. 20. That’s a 17% increase from the week before and it doubled the cases recorded two weeks earlier.
  • d
    dino
    Remember that Pharma stocks tend to be very volatile and news and or results driven. PFE is in the midst of a long term breakout which will be accompanied with major price swings, in comparison to a drunkin rocket ship pilot plotting a jittery course to the stars.
    This will be the same as your PFE trip, so Notch up and be patient.